Literature DB >> 9242545

Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection.

J J Lefrère1, L Morand-Joubert, M Mariotti, H Bludau, B Burghoffer, J C Petit, F Roudot-Thoraval.   

Abstract

Despite a decade of human immunodeficiency virus (HIV) seropositivity, a few individuals termed as long-term nonprogressors (LTNPs) maintain a stable CD4+ T-cell count for a period of time. The aim of this study was to establish, through the sequential determination of all known predictors of HIV disease, the proportion of such patients having stringent criteria of true long-term nonprogression. Among 249 individuals who were HIV-infected and prospectively followed up over a 10-year period (1985 to 1995), 12 having a CD4+ T-cell count greater than 500/microL (LTNP I group) and 9 having a CD4+ T-cell count less than 500 but stable over time (LTNP II group) after at least 10 years of infection without intervention of antiviral therapy, were studied over the entire follow-up period. The plasma HIV RNA copy number and the serum concentrations of p24 antigen, each anti-HIV antibody, neopterin, beta-2-microglobulin, Immunoglobulin (Ig) G and IgA were determined every 18 months over the study period. Cellular and plasma viremias were cross-sectionaly assayed in all 21 patients. Only two patients had strictly no marker of progression over the follow-up period. They were the only ones who had, over the 10-year period, a viral copy number too low to be detected. The other patients had a viral copy number higher than 400/mL at at least one visit and increasing over the follow-up period, and they evidenced one or more markers of virological or immunological deterioration. Cellular viremia was positive in all patients but two, while plasma viremia was negative in all but one. The population of individuals termed as LTNPs is not virologically and immunologically homogeneous. The majority present biological signs of HIV disease progression. A new pattern of true LTNP can be drawn through stringent criteria based on the whole known predictors. This pattern appears to be rare in HIV-positive population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242545

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen.

Authors:  J C de Quiros; W L Shupert; A C McNeil; J C Gea-Banacloche; M Flanigan; A Savage; L Martino; E E Weiskopf; H Imamichi; Y M Zhang; J Adelsburger; R Stevens; P M Murphy; P A Zimmerman; C W Hallahan; R T Davey; M Connors
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Bias in the estimation of cumulative viremia in cohort studies of HIV-infected individuals.

Authors:  Maia Lesosky; Tracy Glass; Brian Rambau; Nei-Yuan Hsiao; Elaine J Abrams; Landon Myer
Journal:  Ann Epidemiol       Date:  2019-08-23       Impact factor: 3.797

3.  Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells.

Authors:  Sarah Boudová; Haishan Li; Mohammad M Sajadi; Robert R Redfield; C David Pauza
Journal:  J Infect Dis       Date:  2012-03-26       Impact factor: 5.226

4.  Combination of immune and viral factors distinguishes low-risk versus high-risk HIV-1 disease progression in HLA-B*5701 subjects.

Authors:  Melissa M Norström; Marcus Buggert; Johanna Tauriainen; Wendy Hartogensis; Mattia C Prosperi; Mark A Wallet; Frederick M Hecht; Marco Salemi; Annika C Karlsson
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

5.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

6.  HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.

Authors:  Brinda Emu; Elizabeth Sinclair; Hiroyu Hatano; April Ferre; Barbara Shacklett; Jeffrey N Martin; J M McCune; Steven G Deeks
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

7.  Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.

Authors:  Simon J Potter; Christine Lacabaratz; Olivier Lambotte; Santiago Perez-Patrigeon; Benoît Vingert; Martine Sinet; Jean-Hervé Colle; Alejandra Urrutia; Daniel Scott-Algara; Faroudy Boufassa; Jean-François Delfraissy; Jacques Thèze; Alain Venet; Lisa A Chakrabarti
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 8.  Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?

Authors:  Joel N Blankson
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970

9.  A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection.

Authors:  Nesrina Imami; Antonio Pires; Gareth Hardy; Jamie Wilson; Brian Gazzard; Frances Gotch
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Characterization of the molecular determinants of primary HIV-1 Vpr proteins: impact of the Q65R and R77Q substitutions on Vpr functions.

Authors:  Guillaume Jacquot; Erwann Le Rouzic; Priscilla Maidou-Peindara; Marion Maizy; Jean-Jacques Lefrère; Vincent Daneluzzi; Carlos M R Monteiro-Filho; Duanping Hong; Vicente Planelles; Laurence Morand-Joubert; Serge Benichou
Journal:  PLoS One       Date:  2009-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.